Services on Demand
Journal
Article
Indicators
Cited by SciELO
Related links
Similars in SciELO
Share
Insuficiencia cardíaca
On-line version ISSN 1852-3862
Abstract
PORCILE¹, Rafael et al. Remodelación inversa del miocardio y reducción de marcadores inflamatorios en pacientes con insuficiencia cardíaca tratada con sacubitrilo/valsartán. Insuf. card. [online]. 2018, vol.13, n.3, pp.104-109. ISSN 1852-3862.
Reverse myocardial remodeling and reduction of inflammatory markers in patients with heart failure treated with sacubitril/valsartan Objective. To evaluate functional class (FC), markers of inflammation and left ventricular function in patients with myocardiopathy of varied etiology and severe deterioration of systolic function after six months of treatment with sacubitril/valsartan (S/V). Methods. Patients with ejection fraction (EF) ≤40% NYHA FC II-IV medicated with S / V and who are in pharmacological treatment established for at least 3 months. It was titled S / V at maximum tolerated dose together with beta-blockers and mineralocorticoid antagonists. We were made echocardiogram with EF measurement by Simpson’s biplane method, C-reactive protein (CRP) dose, erythrosedimentation (ES) and a 6-minute walk test (6MWT) at baseline and at 6 months of treatment with S/V. The student’s T test and the Kolmogorov-Smirnov & Shapiro-Wilk normality test were applied. Results. We included 18 patients. The mean dose was of S/V 275 mg. A decrease in left ventricular diastolic diameter (LVDD) was observed at 6 months from 64.54 to 61.41 mm; p=0.05 (3.128, 0.29 to 6.285, 95% CI). The left ventricular systolic diameter (LVSD) decreased from 51.20 to 43.69 mm; p=0.002 (7.511, 3.292 to 11.730, 95% CI). The EF increased from 27.78 to 38.94%; p=0.003 (11.167; 18.081 to 4.252; 95% CI). The patients improved their FC at 6 months; p=0.001 (1,111, 0.821 to 1.401, 95% CI). The 6MWT increased after 6 months from 332.22 to 495.00 meters; p=0.001 (162.778; 201.01 to 124.455; 95% CI). Also, the levels of CRP, ES and numbers of hospitalizations decreased significantly. Conclusion. In our population, S/V stopped the ventricular remodeling generating improvement of the EF, with reduction of systemic inflammation and improvement in FC. Promising results from our small sample that requires confirmation larger studies with longer follow-up periods.
Keywords : Sacubitril/valsartan; Reverse remodeling; 6-minute walking test; Ejection fraction improvement; CRP .